Suppr超能文献

在中国注射吸毒者中实现丙型肝炎微消除:一项动态网络建模研究。

Achieving Hepatitis C Micro-Elimination in Chinese Injecting Drug Users: A Dynamic Network Modeling Study.

作者信息

Chen Ying, Bao Yun, Yan Mengxia, Jin Huajie, Yao Kaijie, Zhang Chi, Li Wen, Wu Bin

机构信息

Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 241 Huaihai West Road, Shanghai, 200030, China.

West China School of Pharmacy, Sichuan University, Chengdu, 610000, Sichuan, China.

出版信息

Infect Dis Ther. 2025 Jan;14(1):181-197. doi: 10.1007/s40121-024-01084-0. Epub 2024 Dec 11.

Abstract

INTRODUCTION

The World Health Organization (WHO) has established objectives for eradicating the hepatitis C virus (HCV). People who inject drugs (PWID), a major driver of HCV transmission, are an essential part of China's hepatitis C elimination program. This study aimed to estimate the requisite screening and antiviral treatment levels to achieve these goals among people who inject drugs in China and identify the most cost-effective strategy.

METHODS

This study utilized models based on dynamic social networks to simulate HCV transmission and disease progression among people who inject drugs in China, incorporating a cost-effectiveness analysis from a healthcare perspective.

RESULTS

To achieve the WHO targets, a minimum screening and treatment rate of 10% is required to meet the mortality goal, while a 25% rate is necessary for the incidence goal. The most cost-effective strategy includes a 25% screening rate and a 95% treatment rate. Compared to no intervention, this approach significantly reduces costs by - $85,873.38 (95% CI  - $94,311.16 to  - $77,435.59) and adds 24.66 (95% CI 23.68 to - 25.64) quality-adjusted life years. The intervention is dominant, with a cost-effectiveness ratio of - $3482.29 (95% CI  - $3982.73 to  - $3020.11) per quality-adjusted life year.

CONCLUSION

Achieving the WHO's hepatitis C virus elimination targets among people who inject drugs in China is feasible and cost-saving.

摘要

引言

世界卫生组织(WHO)已制定了消除丙型肝炎病毒(HCV)的目标。注射毒品者(PWID)是HCV传播的主要驱动因素,是中国丙型肝炎消除计划的重要组成部分。本研究旨在估计在中国注射毒品者中实现这些目标所需的筛查和抗病毒治疗水平,并确定最具成本效益的策略。

方法

本研究利用基于动态社会网络的模型,模拟中国注射毒品者中的HCV传播和疾病进展,并从医疗保健角度进行成本效益分析。

结果

为实现WHO目标,达到死亡率目标需要至少10%的筛查和治疗率,而发病率目标则需要25%的比率。最具成本效益的策略包括25%的筛查率和95%的治疗率。与不进行干预相比,这种方法可显著降低成本-85,873.38美元(95%CI -94,311.16美元至-77,435.59美元),并增加24.66个(95%CI 23.68至-25.64)质量调整生命年。该干预措施占主导地位,每质量调整生命年的成本效益比为-3482.29美元(95%CI -3982.73美元至-3020.11美元)。

结论

在中国注射毒品者中实现WHO的丙型肝炎病毒消除目标是可行且节省成本的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b5ac/11782747/6d403c071372/40121_2024_1084_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验